Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension

Internal Medicine

Volumn 50, Issue 20, 2011, Pages 2341-2346

  Shimizu, Masatoshi ^a   Imanishi, Junichi ^a   Takano, Takatsugu ^a   Miwa, Yoichi ^a  

^a Graduate School of Health Sciences   (Japan)

Author keywords

Bosentan; Chronic obstructive pulmonary disease; Early onset pulmonary emphysema; Epoprostenol; Pulmonary hypertension

Indexed keywords

BERAPROST; BOSENTAN; PROSTACYCLIN; SILDENAFIL;

ADULT; AIRWAY OBSTRUCTION; ANXIETY; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART AUSCULTATION; HEART CATHETERIZATION; HUMAN; LABORATORY DIAGNOSIS; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; MALE; ONSET AGE; OXYGEN THERAPY; PULMONARY HYPERTENSION; RESTLESSNESS; SIDE EFFECT; SYSTOLIC HEART MURMUR; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY EMPHYSEMA; SULFONAMIDES; VASODILATOR AGENTS;

EID: 80054765913     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5995     Document Type: Article

References (17)

1. Fujimoto K, Kubo K. The epidemiology of early onset COPD in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Research report of respiratory failure research group of the Japanese Ministry of Health, Labor, and Welfare 2007: 25-30, 2008 (in Japanese)
2. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 137: 39S-51S, 2010
3. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172: 189-194, 2005
4. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127: 1531-1536, 2005
5. Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe pulmonary hypertension associated with COPD. Ann Transplant 5: 8-12, 2000
6. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE; National Emphysema Treatment Trial (NETT) Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166: 314-322, 2002
7. Castaldi PJ, Hersh CP, Reilly JJ, Silverman EK. Genetic associations with hypoxemia and pulmonary arterial pressure in COPD. Chest 135: 737-744, 2009
8. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonaryvascular structure and function in chronic obstructive pulmonary disease. Thorax 43: 183-189, 1988
9. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 19: 632-638, 2002
10. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir 32: 619-628, 2008
11. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 181: 270-278, 2010
12. Cottin V, Khouatra C, Lazor R, Canu P, Cordier JF. To the Editors. Eur Respir J 33: 450-452, 2009
13. Figueroa VR, Perez AH, Lecha EA, Cancelo IR, Ramos DV. Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases. Curr Med Res Opin 23: S49-S53, 2007
14. Valerio G, Bracciale P, Grazia D, Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 3: 15-21, 2009
15. Faller M, Kessler R, Sapin R, et al. Regulation of endothelin-1 at rest and during a short steady-state exercise in 21 COPD patients. Pulm Pharmacol Ther 11: 151-157, 1998
16. Galie N, Hoeper MM, Humbert M, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30: 2493-2537, 2009
17. Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. Longterm follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant 26: 363-369, 2007.